Data in Brief
(Feb 2022)
Data on synthesis and structure–activity relationships of tetrazolato-bridged dinuclear platinum(II) complexes
Seiji Komeda,
Hiroki Yoneyama,
Masako Uemura,
Takahiro Tsuchiya,
Miyuu Hoshiyama,
Tomoya Sakazaki,
Keiichi Hiramoto,
Shinya Harusawa
Affiliations
Seiji Komeda
Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie 513-8670, Japan; Corresponding author.
Hiroki Yoneyama
Department of Pharmaceutical Organic Chemistry, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-1094, Japan
Masako Uemura
Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie 513-8670, Japan
Takahiro Tsuchiya
Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie 513-8670, Japan
Miyuu Hoshiyama
Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie 513-8670, Japan
Tomoya Sakazaki
Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie 513-8670, Japan
Keiichi Hiramoto
Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie 513-8670, Japan
Shinya Harusawa
Department of Pharmaceutical Organic Chemistry, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-1094, Japan
Journal volume & issue
Vol. 40
Abstract
Read online
In this data file, the synthetic procedures for the preparation of a series of anticancer tetrazolato-bridged dinuclear platinum(II) complexes ([{cis-Pt(NH3)2}2(μ-OH)(μ-5-R-tetrazolato-N2,N3)]n+ (n = 1 or 2, tetrazolato-bridged complexes)) and of the bridging ligands of 5-substituted 1H-tetrazoles (5-R-1H-tetrazoles) are described. These compounds were characterized by 1H-, 13C-, 19F- and 195Pt-NMR spectroscopy and mass spectrometry.
Keywords
WeChat QR code
Close
